Clyde Glenn, MD
Psychiatry · Ridgeland, MSNPI 1982612164
Payments from drug & device makers
What this record shows
This record is dominated by grants: $62,487 of the $68,498 with a category attached, or 91.2%. Pfizer accounts for 99.2% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $66,021, more than ten times the $331 reported in 2019. Among psychiatry clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $4566.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$68K
- AbbVie$141
- Axsome Therapeutics, Inc.$124
- Otsuka America Pharmaceutical, Inc.$111
- Ironshore Pharmaceuticals Inc.$92
- Biogen$89
Across 2 payments — averaging $81,243 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$162K
What the payments were for
- Speaking & faculty fees$3,4105%
- Grants$62,48791%
- Travel & lodging$1,8123%
- Food & beverage$7901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $67,941 |
| AbbVie | 4 | $141 |
| Axsome Therapeutics, Inc. | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 2 | $111 |
| Ironshore Pharmaceuticals Inc. | 1 | $92 |
| Biogen | 1 | $89 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,498 in reported general payments places this provider in the 95th percentile of 219 psychiatry providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 12 | $20,358 |
| Aripiprazole | 70 | $13,605 |
| Lurasidone Hcl | 23 | $10,909 |
| Quetiapine Fumarate | 160 | $6,594 |
| Clonazepam | 668 | $5,899 |
| Chlorpromazine Hcl | 26 | $5,732 |
| Paliperidone ErPaliperidone | 12 | $5,032 |
| Ziprasidone Hcl | 34 | $4,893 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 100 | $3,349 |
| Bupropion XlBupropion Hcl | 118 | $3,015 |
| Trazodone Hcl | 169 | $2,379 |
| Atomoxetine Hcl | 28 | $2,090 |
| Lisdexamfetamine Dimesylate | 16 | $2,026 |
| Lorazepam | 153 | $1,987 |
| Doxepin Hcl | 48 | $1,963 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Ridgeland
- Kurt BuechlerRidgeland$1.1M
- Mark WebbRidgeland$12K
- Susan YoungerRidgeland$8K
- Mark McLainRidgeland$6K
- Fawaz AbdrabboRidgeland$4K
- Avani PatelRidgeland$4K
- Maxie GordonClinton$1.3M
- Chasity TorrenceWhitfield$834K
- Jon JacksonJackson$834K
- John NortonJackson$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.